Why the study?
Ongoing limitations to transcatheter aortic valve therapy remain, raising the question of whether it will replace surgical aortic valve replacement in the foreseeable future.
Despite significant advances, TAVR requires further improvements in durability and complication rates before replacing surgical aortic valve replacement as the default therapy for all patients.
Answers are grounded in this paper and cite their sources.
TAVR should remain limited to approved indications; leaves open whether durability and safety gains will support broader use.
PURPOSE OF REVIEW: Transcatheter aortic valve replacement (TAVR) has become the cornerstone for aortic valve intervention since the first implantation in 2002. Recent advances with novel devices and introduction into lower risk cohorts have been successful. In this review, we discuss the ongoing limitations to transcatheter aortic valve therapy and whether it will replace surgical aortic valve replacement in the foreseeable future. RECENT FINDINGS: A better understanding of valve durability, high-grade heart block, and stroke post TAVR has led to practice changes that improve patient outcome. SUMMARY: Although there has been great progress made in treating severe aortic stenosis with TAVR, there are room for improvements before it becomes the default therapy for all patients.
No takes yet. Share an insight, caveat, or question.
Shreenivas et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: